US 10,376,485 B2
Metabolic syndrome ameliorating agent
Zhi-hong Yang, Tokyo (JP); Hiroko Miyahara, Tokyo (JP); Shuhei Takemura, Tokyo (JP); and Akimasa Hatanaka, Tokyo (JP)
Assigned to NIPPON SUISAN KAISHA, LTD., Tokyo (JP)
Appl. No. 14/2,809
Filed by Zhi-hong Yang, Tokyo (JP); Hiroko Miyahara, Tokyo (JP); Shuhei Takemura, Tokyo (JP); and Akimasa Hatanaka, Tokyo (JP)
PCT Filed Feb. 29, 2012, PCT No. PCT/JP2012/055088
§ 371(c)(1), (2), (4) Date Nov. 13, 2013,
PCT Pub. No. WO2012/121080, PCT Pub. Date Sep. 13, 2012.
Claims priority of application No. 2011-047313 (JP), filed on Mar. 4, 2011; application No. 2011-110227 (JP), filed on May 17, 2011; and application No. 2011-205318 (JP), filed on Sep. 20, 2011.
Prior Publication US 2014/0066508 A1, Mar. 6, 2014
Int. Cl. A61K 31/201 (2006.01); A61K 31/231 (2006.01); A23L 33/115 (2016.01); A61K 35/60 (2006.01)
CPC A61K 31/201 (2013.01) [A23L 33/115 (2016.08); A61K 31/231 (2013.01); A61K 35/60 (2013.01)] 10 Claims
 
1. A method of raising blood adiponectin concentrations, and lessening TNF-α concentration comprising administering, to a patient in need thereof,
an oil comprising an effective amount of at least one selected from (a) a monounsaturated fatty acid having 22 carbons, or a salt or an ester thereof, and (b) a monounsaturated fatty acid having 20 carbons, or a salt or an ester thereof,
wherein total amount of (a) the monounsaturated fatty acid having 22 carbons, or a salt or ester thereof, and (b) the monounsaturated fatty acid having 20 carbons, or a salt or an ester thereof is at least 50% by weight of total amount of all fatty acids present in the oil.